AGP Executive Report
Last update: 7 hours agoRegulatory Overhaul (Medical Cannabis): The Bahamas is moving ahead with medical cannabis after signing with Metrc for a digital “seed-to-sale” tracking and licensing platform, plus e-prescription updates via an amended Pharmacy Act. FDA & Vaccines: Moderna’s mRNA seasonal flu vaccine (mFlusiva) is approved for adults 50+ in the U.S., with a faster, more flexible manufacturing path for future strains. RSV Prevention Expansion: The FDA accepted Merck’s sBLA to expand ENFLONSIA (clesrovimab-cfor) to prevent RSV lower respiratory tract disease in children under two at increased risk for their second season. Nephrology Treatment Shift: New discussion weighs where corticosteroids and RAS inhibitors fit now that sparsentan is FDA-approved for FSGS, including how it may displace RAS inhibitors for proteinuria reduction. Oncology Trial Momentum: Summit Therapeutics starts the global phase 2/3 HARMONi-GU1 trial testing ivonescimab plus enfortumab vedotin as first-line urothelial cancer therapy. Healthcare Operations & Safety: OhioHealth plans a $10.2M expansion doubling CT capacity, while interventional teams release an ALARA radiation-safety toolkit to reduce occupational exposure. Pharma Compliance Crackdown: India’s drug rules now let state authorities debar companies submitting fake or misleading data, with due process built in.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
